FDA approves CFC-free Combivent Respimat Inhaler for COPD

The FDA has announced the approval of Combivent Respimat (ipratropium bromide and albuterol sulfate) Inhalation Spray for patients with Chronic Obstructive Pulmonary Disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator. Combivent Respimat contains two different types of medicines that open airways in the lungs to help patients with COPD breathe better. It is an alternative for patients who are currently using Combivent (ipratropium bromide and albuterol sulfate) Inhalation Aerosol which is being phased out because it contains chlorofluorocarbons (CFCs). CFCs are chemical compounds that decrease the ozone layer. Combivent Inhalation Aerosol will not be available after December 31, 2013.